

ASX Announcement

5 November 2021

Regeneus (ASX: RGS) Investor Update Webcast

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today advises the recording of the live webcast and Q&A on **Thursday 4th November** can be viewed on:

Regeneus website <https://regeneus.com.au/investors/>
or from the following link <https://youtu.be/4CMgWsmFT90>

Mr. Rosickas provided an update on the Company's progress with its lead platform technology Progenza™, partnership with the Australian Department of Defence for Sygenus and ongoing strategy. Please note, the webinar did not cover financial updates.

- ENDS -

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. Regeneus' regenerative platform technologies Progenza™ and Sygenus seek to address unmet medical needs in human health markets, focusing on neuropathic pain, osteoarthritis and various skin conditions.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

Hannah Howlett
WE Communications
M: +61 450 648 064
E: WE-AURegeneus@we-worldwide.com

For personal use only